vTv Therapeutics Inc. (VTVT) Stock

vTv Therapeutics Inc. (VTVT) is a Healthcare stock trading at $33.35 (as of 2026-08-21), with a market capitalization of $270.06M and a trailing P/E of 119.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company developing orally administered small-molecule treatments. Its pipeline includes TTP399 for type 1 diabetes, HPP737 for inflammatory diseases and psoriasis, and additional programs such as TTP273 for cystic fibrosis–related diabetes and other agents targeting inflammatory and oxidative-stress pathways.

Understand vTv Therapeutics Inc.: how it makes money

vTv Therapeutics develops orally administered drug candidates for diabetes and inflammatory diseases, advancing programs such as TTP399 for type 1 diabetes and HPP737 for inflammatory diseases and psoriasis.

As a clinical-stage biopharmaceutical company, its long-term value depends primarily on whether its oral pipeline programs, including TTP399 and HPP737, can successfully advance through clinical development.

Business quality (Solid): Clear pipeline focus around orally administered diabetes and inflammatory disease treatments, with operating progress tracked via dosing, but the investment case remains tied to uncertain clinical outcomes.

Valuation: At 63× earnings, VTVT trades 277% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Focused oral diabetes program: TTP399 is an orally administered, small molecule, and liver-selective glucokinase activator intended for type 1 diabetes.
  • Second oral program targets inflammatory disease: HPP737 is an orally administered non-CNS penetrant PDE4 inhibitor intended for inflammatory diseases and psoriasis.

Bear case

  • Clinical development uncertainty: Because vTv is clinical-stage, drug candidates may not achieve the needed clinical results to progress.
  • Dependence on a limited set of programs: The business emphasis is centered on advancing multiple oral programs, including TTP399 and HPP737, so setbacks in any key program can weigh on expectations.
Valuation — source: SEC EDGAR (first-party)
Price$33.35
Market Cap$270.06M
P/E Ratio119.9
EV / EBITDA-56.7
Price / Book3.00
Price / Sales7.33
FCF Yield-3.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity2.5%
Current Ratio14.36
Revenue Growth (YoY)-100.0%
Financial Health — source: SEC EDGAR
Altman Z-Score1.18 (distress)
Valuation vs Sector & Industry
Stock P/E119.9
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector451.7%
vs Industry598.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSAMSARA BIOCAPITAL, LLC ($11.84M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPaul J. Sekhri
Employees23
CountryUS
IPO Date2015-07-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Turn Therapeutics Inc. (TTRX)
  • CAMP4 Therapeutics Corporation (CAMP)
  • Eledon Pharmaceuticals, Inc. (ELDN)
  • ALX Oncology Holdings Inc. (ALXO)
  • Zentalis Pharmaceuticals, Inc. (ZNTL)
  • Immuron Limited (IMRN)
  • Q32 Bio Inc. (QTTB)
  • Emergent BioSolutions Inc. (EBS)
VTVT earnings history · VTVT institutional & insider holders · VTVT KPIs & operating metrics · VTVT financials · VTVT investor presentations & press releases · VTVT SEC filings · VTVT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.